117 related articles for article (PubMed ID: 38544345)
1. Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancer.
Mahon KL; Sutherland SI; Lin HM; Stockler MR; Gurney H; Mallesara G; Briscoe K; Marx G; Higano CS; de Bono JS; Chi KN; Clark G; Breit SN; Brown DA; Horvath LG
Prostate; 2024 Jun; 84(8):747-755. PubMed ID: 38544345
[TBL] [Abstract][Full Text] [Related]
2. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
3. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
4. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
5. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
[TBL] [Abstract][Full Text] [Related]
6. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
[TBL] [Abstract][Full Text] [Related]
7. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.
Nuhn P; Vaghasia AM; Goyal J; Zhou XC; Carducci MA; Eisenberger MA; Antonarakis ES
BJU Int; 2014 Dec; 114(6b):E11-E17. PubMed ID: 24529213
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
[TBL] [Abstract][Full Text] [Related]
10. Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
Zedan AH; Osther PJS; Assenholt J; Madsen JS; Hansen TF
Sci Rep; 2020 Jan; 10(1):227. PubMed ID: 31937854
[TBL] [Abstract][Full Text] [Related]
11. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC).
Ryan CJ; Dutta S; Kelly WK; Russell C; Small EJ; Morris MJ; Taplin ME; Halabi S;
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):66-73. PubMed ID: 31053766
[TBL] [Abstract][Full Text] [Related]
12. Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study.
Conteduca V; Wetterskog D; Castro E; Scarpi E; Romero-Laorden N; Gurioli G; Jayaram A; Lolli C; Schepisi G; Wingate A; Casadei C; Lozano R; Brighi N; Aragón IM; Marin-Aguilera M; Gonzalez-Billalabeitia E; Mellado B; Olmos D; Attard G; De Giorgi U
Eur J Cancer; 2021 Jul; 152():49-59. PubMed ID: 34077818
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer.
George DJ; Halabi S; Healy P; Barak I; Winters C; Anand M; Wilder R; Klein M; Martinez E; Nixon AB; Harrison MR; Szmulewitz R; Armstrong AJ
Prostate; 2019 Nov; 79(15):1752-1761. PubMed ID: 31497882
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.
Mager R; Savko O; Böhm K; Thomas A; Dotzauer R; Borgmann H; Jäger W; Thomas C; Haferkamp A; Höfner T; Tsaur I
Urol Oncol; 2019 Dec; 37(12):999-1005. PubMed ID: 31377168
[TBL] [Abstract][Full Text] [Related]
15. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
19. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
20. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
